News and Press Releases
Prevention and early detection of gastrointestinal cancers take on new importance amidst a younger population
Emerging research on early-onset gastrointestinal cancers highlights need for better prevention, diagnosis and treatment Less invasive, smart technologies could improve participation in and efficacy of GI cancer screening Studies presented...
Category: Other
Posted: June 27, 2024
Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development
Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials June 24 2024, California, US, -Bio-Rad Laboratories, Inc. (NYSE: BIO...
Category: BioManufacturing, Clinical Trials, Drug Discovery
Posted: June 24, 2024
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET
Patients Most In Need Face Obstacles to Participating in Life-Saving Clinical Trials According to a New Milken Institute Report
24 June 2024 -- Washington, DC -- Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 24, 2024
New Phesi proof of concept demonstrates potential of AI-powered digital twins to replace external control arms in clinical trials
Study published in Bone Marrow Transplantation uses real-world clinical data to create virtual digital twin cohorts instead of placebo and standard-of-care comparator arms 20 June 2024 -- Massachusetts, US --...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024
Medigene AG Announces Lead Selection for MDG2021,Expanding TCR-T KRAS Library Targeting Solid Tumours
20 June 2024, Planegg/Martinsried, Germany- Medigene AG (Medigene, the “company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Category: Drug Delivery
Posted: June 20, 2024
Bio-Rad Launches ddSEQ Single-Cell 3′ RNA-Seq Kit for Single-Cell Gene Expression
ddSEQ single-cell 3' RNA-Seq kit and Omnition v1.1 analysis software enable high-quality and affordable single-cell transcription and gene expression to support molecular biology, oncology and drug discovery research 19 June...
Category: Drug Discovery, Other, Pharmaceutical
Posted: June 19, 2024
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery
Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases 17 June 2024, Cambridge, UK - STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 17, 2024
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9...
Category: Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Enterprise Therapeutics appoints Dr Renu Gupta as chief medical officer and Dr Janet Hammond as non-executive director
Appointments bring additional respiratory and late clinical-stage drug development experience as company commences Phase 2a clinical trial of its lead asset 17 June 2024, Brighton, UK -: Enterprise Therapeutics Ltd...
Category: Biotechnology, Pharmaceutical
Posted: June 17, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
China’s Innovent holds potential to change pancreatic cancer treatment landscape with bispecific antibody IBI389, says GlobalData
14 June 2024 - China-based Innovent Biologics recently presented phase 1 study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024...
Category: Biotechnology, Pharmaceutical
Posted: June 14, 2024
New Kite Clinical Research and Real-World Evidence for Yescarta (Axicabtagene ciloleucel) Demonstrate Benefit From Earlier Lines of Treatment
Analysis shows manufacturing of axicabtagene ciloleucel in second-line treatment of relapsed/refractory large B-cell lymphoma can help reduce time from leukaepheresis to infusion vs third-line plus treatment Data builds on previous...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 14, 2024
Tapinarof may mark Dermavant’s first atopic dermatitis approval, says GlobalData
Dermavant's VTAMA (tapinarof), a nonsteroidal, topical AhR-modulating agent, achieved positive phase 3 trial results in atopic dermatitis patients aged two and above, leading to Food and Drug Administration (FDA) acceptance...
Category: Drug Discovery, Pharmaceutical
Posted: June 13, 2024
IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
Bold initiative to boost the capacity of research sites enters Beta testing and piloting 12 June 2024 -- North Carolina, US -- IQVIA today announced the launch of One Home...
Category: Clinical Trials, Drug Discovery, Other
Posted: June 12, 2024
CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT
CluePoints is a cloud-based software platform for Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials, designed to enable safer and more efficient processes and improving data integrity...
Category: Biotechnology, Clinical Trials
Posted: June 12, 2024
SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases
12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024
